High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: A pilot study of virus-activated cytotoxic therapy

Blood

Volumn 117, Issue 26, 2011, Pages 6977-6986

  Uldrick, Thomas S ^a   Polizzotto, Mark N ^a   Aleman, Karen ^a   O'Mahony, Deirdre ^a   Wyvill, Kathleen M ^a   Wang, Victoria ^a   Marshall, Vickie ^b   Pittaluga, Stefania ^a   Steinberg, Seth M ^a   Tosato, Giovanna ^a   Whitby, Denise ^b   Little, Richard F ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 6; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; BACTERIAL ENDOCARDITIS; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CATHETER INFECTION; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONFERENCE PAPER; CONSTIPATION; CYTOPENIA; DIARRHEA; DRUG FATALITY; DRUG INDUCED HEADACHE; DYSGEUSIA; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; INSOMNIA; KAPOSI SARCOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MUCOSA INFLAMMATION; MULTICENTRIC CASTLEMAN DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSFUSION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS LOAD; VOMITING;

EID: 79959858676     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-317610     Document Type: Conference Paper

References (51)

1. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67. (Pubitemid 26016404)
2. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43(8):698-704. (Pubitemid 40066010)
3. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865-1869.
4. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-1280.
5. Teruya-Feldstein J, Zauber P, Setsuda JE, et al. Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma. Lab Invest. 1998;78(12):1637-1642. (Pubitemid 29022240)
6. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236-246.
7. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130-2136. (Pubitemid 32239096)
8. + multicentric Castleman disease (MCD). Histopathology. 2008;53(5):513-524.
9. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72(2):1005-1012. (Pubitemid 28116878)
10. Paulose-Murphy M, Ha NK, Xiang C, et al. Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J Virol. 2001;75(10):4843-4853. (Pubitemid 32381527)
11. Staskus KA, Sun R, Miller G, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73(5):4181-4187. (Pubitemid 29189863)
12. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156(3):743-749. (Pubitemid 30626930)
13. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood. 2001;97(8):2526-2527. (Pubitemid 32291504)
14. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96(6):2069-2073.
15. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25-35. (Pubitemid 351524049)
16. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol. 2009;20(4):775-779.
17. Casper C, Nichols WG, Huang M-L, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632-1634. (Pubitemid 38268952)
18. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS. 2003;14(1):61-62. (Pubitemid 36126995)
19. Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clin Infect Dis. 2000;31(2):602-604. (Pubitemid 32289598)
20. Stary G, Kohrgruber N, Herneth AM, Gaiger A, Stingl G, Rieger A. Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS. 2008;22(10):1232-1234.
21. Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol. 2004;75(3):176-177. (Pubitemid 38263829)
22. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657-662. (Pubitemid 28169643)
23. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836-839. (Pubitemid 351664423)
24. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25(22):3350-3356. (Pubitemid 47325622)
25. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R. Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells. Cancer Res. 2007;67(14):7003- 7010. (Pubitemid 47105549)
26. Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol. 1999;73(6):4786-4793. (Pubitemid 29246738)
27. Gustafson EA, Schinazi RF, Fingeroth JD. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol. 2000;74(2):684-692. (Pubitemid 30036204)
28. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
29. Uldrick TS, Wang V, O'Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350-358.
30. Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G. Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood. 2000;96(4):1599-1601. (Pubitemid 30658500)
31. Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood. 2001;97(7):2173-2176. (Pubitemid 32239103)
32. de Sanjose S, Marshall V, Sola J, et al. Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer. 2002;98(1):155-158. (Pubitemid 34113433)
33. Whitby D, Marshall VA, Bagni RK, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer. 2007;120(2):321-328. (Pubitemid 44956841)
34. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods. 2001;91(2):109-117. (Pubitemid 32119328)
35. Toedter G, Hayden K, Wagner C, Brodmerkel C. Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin Vaccine Immunol. 2008;15(1):42-48. (Pubitemid 351966532)
36. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest. 1997;99(9):2082-2086. (Pubitemid 27203763)
37. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198(1):23-30. (Pubitemid 351920285)
38. Jenner RG, Alba MM, Boshoff C, Kellam P. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol. 2001;75(2):891-902. (Pubitemid 32037291)
39. Lu M. Dissection of the Kaposi's sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol. 2004;78(24):13637-13652. (Pubitemid 39612763)
40. Berezne A, Agbalika F, Oksenhendler E, et al. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103(11):4368-4369. (Pubitemid 38685387)
41. Yarchoan R, Broder S. Preliminary results on the use of dideoxynucleosides in the therapy of AIDS. In: Chanock RM, Lerner RA, Brown F, Ginsberg H, eds. Vaccines 87. Modern Approaches to New Vaccines: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1987;214-224.
42. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986;1(8481):575-580. (Pubitemid 16138382)
43. Klecker RW Jr, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987;41:407-412. (Pubitemid 17058925)
44. Wit FW, Sol CJ, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS. 1998;12(2):218-219. (Pubitemid 28035165)
45. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92: Centre d'information et de soins de l'immunodeficience humaine. AIDS. 2000;14(8):987-993. (Pubitemid 30336059)
46. Gasperini P, Sakakibara S, Tosato G. Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol. 2008;84(4):994-1000.
47. Cannon JS, Nicholas J, Orenstein JM, et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis. 1999;180(3):824-828. (Pubitemid 29411370)
48. Qin Z, Kearney P, Plaisance K, Parsons CH. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leukoc Biol. 2009 Aug 20 [Epub ahead of print].
49. Yarchoan R, Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders: a progress report. N Engl J Med. 1987;316(9):557-564. (Pubitemid 17035567)
50. Fu DX, Tanhehco YC, Chen J, et al. Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res. 2007;13(5):1453-1458. (Pubitemid 46450435)
51. Fu DX, Tanhehco Y, Chen J, et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med. 2008;14(10):1118-1122.